Psychotic complications of long-term levodopa treatment of Parkinson's disease. 1991

A Friedman, and J Sienkiewicz
Department of Neurology, Warsaw Medical Academy, Poland.

The prevalence of psychotic complications of levodopa treatment was assessed in 198 Parkinson patients. The symptoms were seen in 44 (22.2%). Those who developed complications were significantly older at disease onset (63.3 +/- 9.2 vs 57.6 +/- 11.6). The observed psychiatric symptoms were classified into two categories: simple, including incidents of confusion alone or hallucinations with preserved insight, and complex, including delusions or chronic confusion without preserved insight. Patients with complex symptoms were significantly younger at the onset of the disease, and the duration of the disease prior to these psychiatric symptoms was longer than in the group of patients with simple symptomatology. Patients with complex symptoms were more susceptible to another central side-effect of the treatment: dyskinesias, than those with simple.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009460 Neurologic Examination Assessment of sensory and motor responses and reflexes that is used to determine impairment of the nervous system. Examination, Neurologic,Neurological Examination,Examination, Neurological,Examinations, Neurologic,Examinations, Neurological,Neurologic Examinations,Neurological Examinations
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011605 Psychoses, Substance-Induced Psychotic organic mental disorders resulting from the toxic effect of drugs and chemicals or other harmful substance. Psychoses, Drug,Psychoses, Toxic,Substance-Induced Psychoses,Toxic Psychoses,Drug Psychoses,Psychoses, Substance Induced,Substance Induced Psychoses
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Friedman, and J Sienkiewicz
January 1996, Archives of gerontology and geriatrics,
A Friedman, and J Sienkiewicz
September 1984, Srpski arhiv za celokupno lekarstvo,
A Friedman, and J Sienkiewicz
December 1970, Neurology,
A Friedman, and J Sienkiewicz
February 1974, Journal of chronic diseases,
A Friedman, and J Sienkiewicz
December 1970, Neurology,
A Friedman, and J Sienkiewicz
January 1988, Archives of neurology,
A Friedman, and J Sienkiewicz
April 1986, Archives of neurology,
A Friedman, and J Sienkiewicz
March 1977, Lancet (London, England),
A Friedman, and J Sienkiewicz
January 1983, Acta neurologica Scandinavica. Supplementum,
Copied contents to your clipboard!